Home » Topics » Disease categories and therapies » Hematologic

Hematologic
RSS

Antithrombin III advances to phase II

Dec. 11, 1996

Allelix reports thrombospondin-derived antihemorrhagic peptide

Dec. 11, 1996

New thrombin inhibitors under study at Merck & Co.

Dec. 9, 1996

Vascular Therapeutics licenses Recordati compound

Dec. 4, 1996

Merck reveals new thrombin inhibitor series

Dec. 3, 1996

3DP seeks partners for protease inhibitor discovery program

Nov. 29, 1996

Merck & Co. reports nonpeptide fibrinogen antagonists with oral activity

Nov. 28, 1996

Potent, orally active antiplatelet agent discovered by Merck & Co.

Nov. 28, 1996

Natural antiplatelet agent discovered at Kitasato Institute

Nov. 28, 1996

RESTORE trial results presented at AHA meeting

Nov. 22, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
FDA greenlights Medtronic Onyx subdural hematoma treatment
BioWorld MedTech
Sometimes the darkest products (names) bring a bright spot of news to their developers, as the U.S. FDA clearance for Galway, Ireland-based Medtronic plc's Onyx...